



Scott Langille

Chief Financial Officer

Mr. Scott Langille has over 30 years of experience in the pharmaceutical industry in both Canada and the United States. Mr. Langille was Chief Financial Officer of Tribute Pharmaceuticals, which is listed on the Toronto Venture Stock Exchange and the OTC QB exchange in the U.S. and was sold to Pozen in February 2016 for \$160M \$U.S. to create Aralez Pharmaceuticals. Prior to Tribute Pharmaceuticals, Mr. Langille was Chief Financial Officer of Virexx Medical Corp, a biotechnology company located in Alberta listed on both the American Stock Exchange and the Toronto Stock Exchange.

Past financial experience includes Director, Corporate Finance at Biovail Corporation, Director of Finance at Biovail Pharmaceuticals Canada, Biovail's sales and marketing division in Canada as well as Vice President at Biovail Pharmaceuticals Inc., Biovail's sales and marketing division in the United States. Other prior management positions include Director of Finance at AltiMed Pharmaceuticals Company and Controller at Zimmer Canada. Scott has a professional accounting designation and an MBA from the University of Toronto.